Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ford, Andria L
NCT04611880: Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)	Active, not recruiting	2	20	US	Crizanlizumab, ADAKVEO	Washington University School of Medicine	RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy	01/24	08/27
CRIZ, NCT05334576: Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA	Recruiting	N/A	31	US	Crizanlizumab	Andria Ford, Novartis Pharmaceuticals	Sickle Cell Disease	07/24	07/25